WCM Investment Management LLC Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

WCM Investment Management LLC raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,179,011 shares of the life sciences company's stock after purchasing an additional 49,156 shares during the quarter. WCM Investment Management LLC owned 2.64% of Illumina worth $334,321,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Rakuten Securities Inc. raised its holdings in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new position in Illumina in the 1st quarter valued at about $33,000. Fourth Dimension Wealth LLC purchased a new stake in Illumina during the fourth quarter worth about $40,000. PFS Partners LLC increased its stake in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after purchasing an additional 400 shares during the period. Finally, Golden State Wealth Management LLC lifted its position in shares of Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock worth $42,000 after purchasing an additional 292 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Citigroup dropped their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Robert W. Baird dropped their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Royal Bank Of Canada reduced their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Canaccord Genuity Group boosted their target price on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. Finally, Barclays restated an "underweight" rating and set a $85.00 price target (up previously from $77.00) on shares of Illumina in a report on Tuesday, June 24th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and an average target price of $127.39.

Illumina Stock Up 2.2%

ILMN stock traded up $2.19 during trading on Wednesday, hitting $100.34. 2,165,194 shares of the company's stock were exchanged, compared to its average volume of 2,146,048. The business has a 50-day moving average price of $83.64 and a two-hundred day moving average price of $98.31. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $15.88 billion, a price-to-earnings ratio of -16.53, a PEG ratio of 1.87 and a beta of 1.36. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The company's revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.98 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The shares were acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.